Philips Stellarex Clinical Summary: Illuminate Pivotal Randomized Trial
Case study: Severely Calcified SFA Stenosis:
-
Stellarex is the only DCB reported to have durable patency at 2 years in severely calcified lesions
-
Stellarex demonstrates a robust treatment effect over PTA in severely calcified lesions
-
82% of the severely calcified segments were greater than 50% of the total lesion length
D045227-00
